In recent developments, Goldman Sachs has reiterated its "Buy" rating for 4D Molecular Therapeutics (FDMT, Financial). The decision to maintain the rating reflects continued confidence in the company's potential despite a revised price target.
Analyst Salveen Richter from Goldman Sachs announced a reduction in the price target for FDMT, lowering it from the previous target of $51.00 USD to a new target of $44.00 USD. This adjustment represents a 13.73% decrease from the prior target.
The adjustment comes as part of a regular review of the company's performance metrics and market conditions, which led to a more conservative outlook on the stock's future valuation.
Despite the revision, the "Buy" rating indicates that Goldman Sachs still sees potential upside in 4D Molecular Therapeutics (FDMT, Financial) and believes the stock continues to be an attractive investment opportunity.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for 4D Molecular Therapeutics Inc (FDMT, Financial) is $28.50 with a high estimate of $44.00 and a low estimate of $6.00. The average target implies an upside of 842.15% from the current price of $3.03. More detailed estimate data can be found on the 4D Molecular Therapeutics Inc (FDMT) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, 4D Molecular Therapeutics Inc's (FDMT, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for 4D Molecular Therapeutics Inc (FDMT, Financial) in one year is $0.05, suggesting a downside of 98.35% from the current price of $3.025. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the 4D Molecular Therapeutics Inc (FDMT) Summary page.
